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CommentaryThe past twenty years have wit-
nessed a dramatic expansion in the 
capacity of developing nations to 
conduct basic research and to apply 
that research to solving such critical 
issues as food security, public health, 
and environmental protection. As a 
result, important steps have been 
taken on the road to curbing poverty 
and promoting human development.
A key challenge faced by devel-
oping countries in trying to conduct 
basic research has resided in build-
ing basic scientific capacity. That 
has meant providing adequate fund-
ing for education and training and 
for constructing laboratories that 
could fulfill the needs of faculty and 
students alike. Today, these chal-
lenges remain stubbornly in place 
in many developing nations. Never-
theless, more and more developing 
countries have passed a threshold 
of basic competency and are now 
seeking to strengthen and broaden 
what has become a firm foundation in 
research.
Rising Optimism
There are a number of key success 
stories in the developing world. China 
has built a formidable infrastructure in 
the life sciences in just two decades, 
demonstrating growing capabilities in 
bioinformatics, genomics, and stem 
cell research. In 1986, for example, 
China launched the National High 
Technology R&D Program. By 2001, 
the program was providing fund-
ing for some 20,000 researchers 
and administrative staff in more 
than 3,000 research institutions 
(http://www.oti.globalwatchonline.
com/online_pdfs/36206MR.pdf ). 
India has developed a profitable 
pharmaceutical industry that has 
manufactured an impressive list of 
recombinant vaccines against polio, 
rabies, hepatitis B, and typhoid 
(Kumar et al., 2004). Brazil is focus-
ing its efforts on training young sci-
entists and on applying its growing 
expertise in the life sciences both 
to take advantage of its unmatched 
biodiversity and to become a world 
leader in biofuels (TWAS Newsletter, 
2006). The number of articles pub-
lished by Argentinean scientists in 
peer-reviewed international journals 
continues to increase, and the nation 
has taken a global leadership posi-
tion in cultivating genetically modified 
(GM) crops (Roca et al., 2004). Malay-
sia has efficiently raised its skill levels 
in the life sciences and is now seek-
ing to build a vibrant commercial sec-
tor in the fields of biotechnology and 
genetic engineering (Shah, 2006). 
South Africa has emerged as the pri-
mary center of research and devel-
opment in the life sciences in Africa 
(Motari et al., 2004). Cuba is a leading 
developing nation in the life sciences, 
earning an international reputation 
for the development and manufac-
ture of vaccines (Thorsteinsdóttir et 
al., 2004). The emphasis that these 
countries have placed in developing 
life sciences research demonstrates 
a clear “take home” message that 
scientific competency is difficult to 
displace once it has taken root.
The welcome change in the sci-
entific competence of certain devel-
oping countries can also be seen in 
the increasing number of universi-
ties and research institutes that have 
created or expanded departments 
in biology and related fields such as 
bioinformatics and genetic engineer-
ing. Brazil’s Oswald Cruz Foundation 
and Butantan Institute have played 
leading roles in the nation’s growing 
prowess in the life sciences, particu-
larly biotechnology. China’s Beijing 
Genomics Institute and the Chinese 
National Human Genome Center 
operate state-of-the-art sequencing 
facilities and have participated fully in 
international efforts to advance these 
fields, including the Human Genome 
Sequencing Project (making China 
the only developing country to do 
so). The Indian Institute of Science’s 
broad portfolio of research initiatives 
includes immunology and reproduc-
tive biology for vaccine development 
to combat malaria and tuberculosis. 
India’s National Institute of Immunol-
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ogy and Institute of Microbial Technol-
ogy have acquired international repu-
tations for their work on biomedicine, 
diagnostics, and protein structure.
This change in scientific compe-
tence is also visible in the small but 
steadily increasing number of pri-
vate firms that are engaged in sell-
ing agricultural and health-related 
biotechnology products and ser-
vices both within their own coun-
tries and abroad. In 1993, Brazil was 
home to 76 biotechnology firms; by 
2004, the Brazilian Association of 
Biotechnology estimated the num-
ber of core biotechnology firms to 
be 150; other sources have placed 
the number at more than 300 (Niosi 
and Reid, 2007). The number of bio-
technology firms in China is esti-
mated to be ~130 (Ernst and Young, 
2004)—some state-owned commer-
cial enterprises, others small private 
firms—and they benefit from a huge 
population that allows for domes-
tic clinical assays and a large pool 
of students who have often been 
trained overseas but increasingly 
are returning home to pursue their 
careers (Louet, 2004). India’s 350 
plus private firms are aggressively 
seeking to move up the innovation 
ladder from companies that manu-
facture inexpensive generic ver-
sions of existing pharmaceuticals to 
companies creating new high-value 
products (BioSpectrum India, 2007). 
Shantha Biotechnics is the first com-
pany in India to produce a recombi-
nant DNA hepatitis B vaccine; this 
vaccine has been prequalified by 
the World Health Organization and 
is being supplied to United Nations 
agencies for distribution in poor 
countries. This home-grown com-
pany also created India’s first 4-in-1 
vaccine against diphtheria, tetanus, 
pertussis, and hepatitis (Frew et al., 
2007). Cuba, home to some of the 
best life science research centers 
in the developing world, has cre-
ated “commercial” divisions in its 
state-owned institutions for the sale 
of vaccines to combat meningitis B, 
hepatitis B, and pneumonia (Thor-
steinsdóttir et al., 2004).
Another visible display of the 
change in scientific competence 434 Cell 131, November 2, 2007 ©2007 Eand the willingness to embrace 
scientific advances lies in the cul-
tivation of GM crops. Since the 
US Food and Drug Administration 
licensed the world’s first GM crop, 
Flavr Savr tomato, in 1994, the 
amount of farmland devoted to GM 
crops worldwide has doubled each 
year and now exceeds 100 million 
hectares. More than 10 million farm-
Figure 1 South-South Cooperation
(Top) Citarasu Thavasimuthu, an Indian marine 
biotechnologist from Chennai, India, working as 
a postdoctoral fellow in Wuhan, China in 2005 
in a program funded by the Chinese Academy 
of Sciences (CAS) and TWAS, The Academy of 
Sciences for the Developing World. 
(Middle) Oluwatoyin Rebecca Afolabi, an in-
dustrial microbiologist from Abeokuta, Nigeria, 
working as a postdoctoral fellow in the Cen-
ter for DNA Finger Printing and Diagnostics in 
Hyderabad, India in 2006. Her fellowship was 
funded by India’s Department of Biotechnol-
ogy (DBT) and TWAS. 
(Bottom) Biochemist Mushtaq Ahmed from 
Bannu Township in Pakistan is currently a 
postgraduate fellow at the Universidade Fed-
eral de Santa Maria in Brazil funded by CNPq 
(the government department that funds re-
search in Brazil) and TWAS. 
Photographs courtesy of TWAS.lsevier Inc.ers in 22 countries grow GM crops, 
and more than 40% of the agricul-
tural land devoted to GM crops is 
in the developing world (James, 
2006). Argentina is second only to 
the United States in hectares culti-
vated with GM crops; Brazil is third. 
Last year, India supplanted China 
as number four on the list. Para-
guay, South Africa, Uruguay, and 
the Philippines are each in the top 
10. All told, half of the 22 countries 
that grow GM crops are developing 
nations.
Mind the Gaps
The North-South capacity gap in 
the life sciences continues to nar-
row, but it has by no means disap-
peared. At the same time, a new gap 
in capacity has emerged between 
scientifically proficient developing 
countries and scientifically lagging 
developing countries—the so-called 
South-South gap. This divide has 
surfaced because the number of 
developing countries making sig-
nificant strides in building scientific 
capacity remains small (Argentina, 
Brazil, Chile, China, Cuba, India, 
Malaysia, Mexico, and South Africa). 
Meanwhile, the number of coun-
tries that have not made significant 
strides is large and includes most of 
the countries in sub-Saharan Africa 
and countries with predominantly 
Muslim populations. However, there 
are examples of increasing South-
South cooperation that are help-
ing to close this gap, exemplified 
by China’s $5 billion Development 
Fund for Africa and Brazil’s Pro-Af-
rica Program that funds science and 
technology projects in sub-Saharan 
Africa (Hassan, 2007). There is also 
an increase in the number of post-
graduates and postdoctoral fellows 
moving from one part of the South-
ern hemisphere to another to obtain 
further training (see Figure 1). 
There are, as well, valiant efforts 
within Africa to forge new levels of 
cooperation on science and tech-
nology. In 2003, the first ministe-
rial meeting of the New Partnership 
for Africa’s Development (NEPAD) 
called for Africa’s leaders to seek 
a common position on biotechnol-
ogy (Mugabe, 2003; Panos, 2005; 
Thompson, 2004). In 2005, the 
African Union (AU) established a 
14-member high-level group, co-
chaired by Calestous Juma, direc-
tor, Science, Technology and Glo-
balization, Harvard University, and 
Ismail Serageldin, director, Biblioth-
eca Alexandria in Egypt, to advise 
AU members on how advances in 
biotechnology would affect agricul-
ture, health, and the environment in 
Africa (Chege, 2005). The panel’s 
report Freedom to Innovate: Bio-
technology in Africa’s Develop-
ment, published several months 
ago, analyzes the opportunities 
and risks that the life sciences 
pose for the world’s poorest region 
(Juma and Serageldin, 2007). This 
public debate is good for science 
in general and the life sciences in 
particular and is emblematic of the 
public’s increasing interest in sci-
ence in Africa.
At the annual AU summit meeting 
this year, African leaders pledged to 
establish national and regional cen-
ters of excellence in science and 
technology and to allocate at least 
1% of their gross domestic product 
(GDP) to research and development 
by 2020. Indeed, a number of Afri-
can nations have already increased 
expenditure on science. For exam-
ple, Rwanda has increased science 
spending to 1.6% GDP and South 
Africa plans to raise R&D spend-
ing to 1% of GDP by 2009 (Has-
san, 2007). Modeled after the Indian 
Institutes of Technology spread 
across the Indian subcontinent, the 
planned African Institute of Science 
and Technology (AIST) will consist 
of several higher education cam-
puses across sub-Saharan Africa. 
The first AIST campus is under con-
struction in Abuja, Nigeria and will 
open its doors to students in Sep-
tember 2008.
These recent measures indicate 
that Africa is increasingly deter-
mined to control its own destiny in 
both the development and applica-
tion of life sciences. For example, 
there are efforts to develop phar-
maceuticals based on knowledge 
of indigenous and medicinal plants. These initiatives speak well for the 
future of science across the con-
tinent, making science in Africa 
more relevant to society and more 
accountable.
Public and Private Affairs
Even developing countries that have 
successfully strengthened their sci-
entific capacity have proven more 
adept at building their knowledge 
base than at applying the knowl-
edge that their scientists acquire 
to address societal concerns. The 
most critical shortfall in these efforts 
has been an inability to forge strong 
links between universities/research 
institutes, largely funded by govern-
ments, and the private sector, which 
is admittedly weak in most develop-
ing countries. For example, experts 
estimate that more than 60% of 
global research and development 
in biotechnology is funded by the 
private sector (Charlafti, 2003). Yet, 
even among the most advanced 
developing countries, the private 
sector has made only marginal con-
tributions to such efforts, which 
remain almost exclusively funded 
by national governments.
To gain parity with the devel-
oped world, developing countries 
will need to strengthen and stimu-
late the private sector and then 
encourage the creation of durable 
partnerships between government, 
research institutes, and nascent pri-
vate companies. This is beginning 
to take place in several countries, 
notably Brazil, China, India, and, to 
a lesser extent, Malaysia and South 
Africa. But the pace of reform must 
quicken if the capacity gap between 
the North and South is to close at a 
more rapid and even pace.
Science and Society
Scientists in both developed and 
developing countries should not 
be shy about speaking out against 
viewpoints that they feel ignore sci-
entific truths. Rather than viewing 
public discussions as fruitless dis-
tractions, scientists should welcome 
such engagements as opportunities 
to speak out about the importance 
of their work beyond the familiar Cell 131, Noboundaries of the scientific commu-
nity. As the life sciences continue 
to become stronger in developing 
countries and as applications of the 
ever-expanding knowledge base 
gain greater presence across the 
South, the dialog between the sci-
entific community and society will 
no doubt intensify, and scientists 
should be prepared.
National, merit-based science 
academies represent an often-ne-
glected but potentially significant set 
of institutions that could play a vital 
role in helping to build capacity in the 
life sciences in developing countries 
and in bridging the science-society 
gap in the biological sciences. The 
public often thinks of these institu-
tions as places where eminent sci-
entists politely exchange ideas and 
socialize at a leisurely gentlemanly 
pace. But science academies are 
also places of extraordinary scien-
tific talent and expertise. They have 
only recently begun to change their 
ways, seeking to make the store-
house of knowledge that their mem-
bers possess more accessible and 
useful to society.
Science academies could ulti-
mately serve as responsible inter-
mediaries between science and 
society—knowledge-based bro-
kers for the public good—that 
would help to explain the complex-
ities of the life sciences to lay citi-
zens while simultaneously forging 
useful links between the scientific 
community and the public. Giving 
independent, unbiased advice to 
governments on science-based 
issues of critical importance to 
society may prove to be the most 
significant contribution that sci-
ence academies can make.
It is clear that in the minds of 
many political leaders in the South, 
the life sciences in general and bio-
technology in particular are on par 
with information and communica-
tion technologies, representing a 
truly transformational knowledge 
base that serves a fundamental role 
in national efforts to build success-
ful societies capable of competing 
in today’s global economy. A key 
issue that concerns both devel-vember 2, 2007 ©2007 Elsevier Inc. 435
oped and developing nations alike 
is the capacity to know, learn, and 
apply the world’s growing scientific 
expertise in wise, productive, and 
safe ways. This is especially true in 
the life sciences where advances in 
research and technology are likely 
to shape and reshape our world in 
untold ways in the years ahead.
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